Application of Verteporfin in preparation of medicine for resisting novel coronavirus SARS-CoV-2

A technology of verteporfin and coronavirus, applied in the field of medicine, can solve the problem that verteporfin has not been seen to inhibit coronavirus, etc., and achieve the effect of inhibiting infection

Pending Publication Date: 2021-10-26
FUDAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there has been no report on the application of verteporfin in inhibitin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Verteporfin in preparation of medicine for resisting novel coronavirus SARS-CoV-2
  • Application of Verteporfin in preparation of medicine for resisting novel coronavirus SARS-CoV-2
  • Application of Verteporfin in preparation of medicine for resisting novel coronavirus SARS-CoV-2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] The inhibitory effect of different concentrations of verteporfin on the infection of SARS-CoV-2 on Vero-E6 cells was observed by cytopathic (CPE):

[0028] Inoculate Vero-E6 cell suspension (4 × 10 4 cells / well), the culture plate was placed in the incubator for pre-cultivation for 12 hours, and the cells adhered to the wall for growth;

[0029] Add the corresponding concentration of verteporfin to pre-treat for 1 hour, add DMSO to the solvent control, and add no drug to the negative control;

[0030] Then add 200PFU SARS-CoV-2 virus (GenBank: MT121215.1) to each well except the negative control. After 12 hours of infection, wash twice with PBS, add new medium containing verteporfin, and incubate at 37°C After 48 hours, the cytopathic changes were observed under the microscope.

[0031] Experimental results such as figure 1 As shown, the experimental results show that normal Vero-E6 cells (negative control) grow normally after 48 hours of culture, and no cytopathic c...

Embodiment 2

[0033] The inhibitory effect of different concentrations of verteporfin on the infection of SARS-CoV-2 on Vero-E6 cells was observed by indirect immunofluorescence experiment:

[0034] Cells were processed as in Example 1, and washed 2 times with PBS after virus infection for 48 hours, each time for 5 minutes;

[0035] Add 4% paraformaldehyde to fix at room temperature for 15 minutes;

[0036] Discard the solution, add PBS solution containing 0.5% Triton X-100, react at room temperature for 10 minutes, wash with PBS twice, 5 minutes each time;

[0037] Add freshly prepared PBS solution containing 5% BSA, block at room temperature for 1 hour, wash with PBS twice, 5 minutes each time;

[0038] Add 1:1000 diluted mouse anti-N protein (SARS-CoV-2) polyclonal antibody, and react at room temperature for 1 hour;

[0039] Wash with PBS 3 times, 5 minutes each time;

[0040] Add FITC-goat anti-mouse IgG secondary antibody diluted 1:10000, react at room temperature for 1 hour; wash w...

Embodiment 3

[0045] Real-time quantitative PCR (Q-RT-PCR) method was used to detect the viral copy number of Vero-E6 cell supernatant to verify the inhibitory effect of verteporfin on the infection of SARS-CoV-2:

[0046] Cells are processed as in example 1 step;

[0047] After 48 hours, the cell supernatant was collected for RNA extraction.

[0048] RNA extraction:

[0049] Add 100 μL of cell supernatant to 300 μL TRIzol lysate, mix well and lyse;

[0050] Add 200 μL of chloroform and shake vigorously, let stand for 2-3 minutes, then centrifuge at 12000g for 15 minutes at 4°C;

[0051] Aspirate the supernatant, add 500 μL isopropanol, let stand for 10 minutes, and then centrifuge at 12000g for 10 minutes at 4°C;

[0052] Add 1 mL of 75% ethanol to wash the RNA pellet; centrifuge at 7500g for 5 minutes at 4°C;

[0053] Discard 75% ethanol, add 20-50 μL water to dissolve the RNA precipitate after drying;

[0054] RNA reverse transcription:

[0055] For reverse transcription of RNA, cD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines and relates to a novel medicinal application of Verteporfin, in particular to an application of the Verteporfin in preparation of a medicine for resisting a novel coronavirus SARS-CoV-2. Experiments prove that the infection of the novel coronavirus can be effectively inhibited through intervention of in-vitro cell culture Vero-E6 (African green monkey kidney cells) by the Verteporfin, and novel coronavirus diseases caused by the novel coronavirus can be further treated by medicines prepared from the Verteporfin, so that a new medicine is provided for treating and controlling the novel coronavirus diseases.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a new medicinal use of verteporfin, in particular to the use of verteporfin in preparing anti-new coronavirus SARS-CoV-2 drugs. Background technique [0002] Novel coronavirus disease (Corona Virus Disease 2019, COVID-19), also known as novel coronavirus pneumonia, is a severe acute respiratory infectious disease. The disease is highly infectious and has a high fatality rate. The pathogen causing novel coronavirus disease is novel coronavirus (SARS-CoV-2). SARS-CoV-2 and the known severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the betacoronavirus genus of the Coronaviridae family. [0003] Clinical practice shows that common symptoms after people are infected with SARS-CoV-2 include respiratory symptoms, fever, cough, shortness of breath, and dyspnea. In more severe cases, infection can lead to pneum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/409A61P31/14
CPCA61K31/409A61P31/14
Inventor 谢幼华谷陈建郭慧敏吴旸瞿涤袁正宏张荣王玉燕朱园飞徐巍
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap